Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 15/20 | 0.56 |
| ▸ | CCR3 | P51677 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PDE6D | O43924 | 1/20 | 0.43 |
| ▸ | PDE6A | P16499 | 1/20 | 0.43 |
| ▸ | PDE6G | P18545 | 1/20 | 0.43 |
| ▸ | PDE6B | P35913 | 1/20 | 0.43 |
| ▸ | PDE6C | P51160 | 1/20 | 0.43 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.43 |
| ▸ | PGK1 | P00558 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5596051 | 0.93 | PDE5A (0.54) | PDE5AMAPTTSHR | |
| SCHEMBL5595464 | 0.87 | PDE5A (0.59) | PDE5AMAPK1PDE6DPDE6APDE6G | |
| SCHEMBL5595851 | 0.86 | PDE5A (0.52) | PDE5AKDM4EALDH1A1PDE6DPDE6A | |
| SCHEMBL7164961 | 0.85 | PDE5A (0.62) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL7159372 | 0.81 | PDE5A (0.61) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL7168340 | 0.81 | PDE5A (0.60) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL5596279 | 0.79 | PDE5A (0.60) | PDE5A | |
| SCHEMBL7164790 | 0.78 | PDE5A (0.57) | PDE5AMAPTGAAPDE6DPDE6A | |
| SCHEMBL7163538 | 0.77 | PDE5A (0.59) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL5596373 | 0.76 | PDE5A (0.67) | PDE5APDE6DPDE6APDE6GPDE6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7173042-B2 | Quinoline inhibitors of cGMP phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | claimed |
| US-20050113358-A1 | Quinoline inhibitors of cGMP phosphodiesterase | BI YINGZHI (US) | 2005-05-26 | — | — | US | claimed |
| US-6835737-B2 | For treating conditions such as erectile dysfunction, cardiovascular disorders, male or female sexual dysfunction, diabetes mellitus, and gastrointestinal disorders | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-28 | — | — | US | claimed |
| US-20030225128-A1 | Quinoline inhibitors of cGMP phosphodiesterase | BI YINGZHI (US) | 2003-12-04 | — | — | US | claimed |
| US-20020177587-A1 | Quinoline inhibitors of cGMP phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113358-A1 | Quinoline inhibitors of cGMP phosphodiesterase | PDE5A, PDE3A, PDE2A | PDE5A 1/4885CCR3 4702/4885MAPT 4301/4885 |
| US-20030225128-A1 | Quinoline inhibitors of cGMP phosphodiesterase | PDE5A, PDE3A, PDE2A | PDE5A 1/4885CCR3 4714/4885MAPT 4486/4885 |
| US-20020177587-A1 | Quinoline inhibitors of cGMP phosphodiesterase | PDE5A, PDE2A, PDE3A | PDE5A 1/4885CCR3 4569/4885MAPT 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.